Royal Bank of Canada reissued their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a report published on Tuesday morning, Benzinga reports. The firm currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their target price on shares of Hookipa Pharma from $6.50 to $5.00 and set […]
Royal Bank of Canada reaffirmed their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their price target on shares of Hookipa Pharma from […]
HC Wainwright Weighs in on Hookipa Pharma Inc's Q1 2025 Earnings (NASDAQ:HOOK) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or.